The company emphasized confidentiality, stating that the contract partner will remain undisclosed until December 31, 2031. While the contract value represents 1.94% of last year's revenue, the market is keenly anticipating the possibility of this being an initial order. With the operation of Plant 4 and the expansion of Plant 5, line utilization is expected to increase further. A blended strategy of biosimilar and novel drug contracts is considered key to broadening the customer base. Despite inflation, interest rates, and policy variables in the U.S. and Europe, the scale advantages of large CDMOs are becoming more prominent. It is interpreted that the expanded sales scope, from 'Top 20' to 'Top 40,' has led to actual contracts. Anonymous partnerships increase the likelihood of high-value late-stage process or multi-product contracts. Delayed disclosure clauses are evidence of confidentiality linked to pipeline launch calendars. The recent clustering of demand for anticancer and metabolic disease monoclonal antibodies is also a positive factor. Portfolio diversification and production flexibility must be simultaneously met to maintain yield and cost efficiency. Samsung Biologics' process standardization, digital batching, and QA automation are the basis for its cost competitiveness. The won-dollar exchange rate and tariff issues actually enhance the appeal of offshore production bases. The third-quarter conference call will be a turning point to see if the 'conservative guidance—upward performance' formula will be repeated. Investors should monitor the potential for long-term orders and the timing of line expansions. It is also necessary to compare the production capacity development of competing CDMOs. This contract exemplifies a typical big pharma deal, combining 'economy of scale + security.' Domestic bio value chains are expected to see co-benefits in raw materials, analysis, and logistics. Ultimately, the key is 'time': the pipeline and revenue recognition that will be revealed at the time of disclosure. If additional large anchor deals are secured in the second half of the year, it will strengthen the argument that the industry has bottomed out.